31 July 2013
The Kaluga region in Central Russia, the city of Kaluga and NovaMedica, a young Russian pharma, have agreed to build a new pharmaceutical factory in the area, Rusnano reports .
The new project is part of a joint effort between Rusnano, Russia’s largest nanotech company, and Domain Associates, a leading US-based VC fund. NovaMedica is a year-old subsidiary of the Russian and American partners in the effort.
The factory is expected to manufacture innovation drugs and medical products that will be authorized for Russia-based production within the framework of Rusnano and Domain Associates’ broader joint program designed to fund pharma and biomed projects at advanced stages of research.
Under the terms of this most recent agreement, the partners will build in Kaluga’s Grabtsevo Techno-park a high-tech pharmaceutical production line to comply with the GMP standards. It is expected to be sophisticated enough for its products to be approved by the U.S.’ Food and Drug Administration (FDA).
This $85m factory is also expected to create more than a hundred new local jobs.
The production facility will break ground later this year, Rusnano said.
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
A Moscow region manufacturer of blood collection systems is expanding its capacity
22 January 2025
A biotechnology and medicine center has opened in Mordovia
22 January 2025
Long-term potential revealed for novel modifier gene therapy
21 January 2025
Binnopharm Group opened an office in Vietnam
21 January 2025